使用皮质类固醇减轻转氨酶升高相关凝血因子VIII水平下降:valoctocogene roxaparvovec基因治疗后的临床实践指导
本文针对接受valoctocogene roxaparvovec基因治疗的成人重型A型血友病患者,基于现有临床数据与专家意见,提供使用皮质类固醇评估和管理转氨酶升高以减轻凝血因子VIII活性潜在下降的实践指导。转氨酶升高是该基因治疗试验中最常见的不良事件,通常轻微且短暂,部分患者伴随FVIII水平降低,一般采取反应性皮质类固醇疗程管理。
要点
- 转氨酶升高是valoctocogene roxaparvovec临床试验中最常见的不良事件,通常轻微且短暂。
- 部分患者转氨酶升高时伴随FVIII水平降低,一般采取反应性皮质类固醇疗程管理。
- 本文基于现有临床数据与专家意见提供管理转氨酶升高的实践指导。
核心结论
- 本文基于现有临床数据和专家意见,为接受valoctocogene roxaparvovec的成人重型A型血友病患者提供使用皮质类固醇评估和管理转氨酶升高以减轻FVIII活性潜在下降的实践指导。
研究设计与样本
- 本文为论坛文章(forum article),基于现有临床数据和专家意见提供实践指导。
主要发现
- 转氨酶升高是valoctocogene roxaparvovec临床试验中最常见的不良事件,通常轻微且短暂。
- 转氨酶升高这一肝细胞损伤标志物在部分患者中与FVIII水平降低同时出现,一般采取反应性皮质类固醇疗程管理。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Valoctocogene roxaparvovec is the only factor VIII (FVIII) gene therapy currently approved for adults with severe hemophilia A in Europe and the USA. Elevated alanine transaminase (transaminitis) has been the most common adverse event observed during valoctocogene roxaparvovec clinical trials. Typically mild and transient, this marker of hepatocyte injury coincides, in some patients, with reduced FVIII levels and is generally managed with a reactive course of corticosteroids. An essential step in optimizing outcomes for patients who receive valoctocogene roxaparvovec is reviewing the extensive evidence currently available on this topic to determine practices for managing transaminitis, if it occurs. This forum article provides practical guidance based on the available clinical data and expert opinion for evaluating and managing transaminitis with corticosteroids to mitigate potential declines in FVIII activity levels in adults with severe hemophilia A who have received valoctocogene roxaparvovec.
引用
- Konkle BA, Peyvandi F, Foster GR, et al. Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. J Thromb Haemost. 2025. PMID: 40090623. doi:10.1016/j.jtha.2025.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。